PharmaTelevision - Brandon Capital Partners: Dr David Fisher discusses their role in Medical Research Commercialization Fund

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Brandon Capital Partners: Dr David Fisher discusses their role in Medical Research Commercialization Fund

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Dr David Fisher, Venture Partner of Brandon Capital Partners

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Types of funds and investments

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at AusBiotech's convention in Adelaide. On this show I have David Fisher, who is a Venture Partner at Brandon Capital , welcome.

David Fisher:

Thank you.

Fintan Walton:

David, you've been an active investor in biotechnology companies here in Australia for some time.

David Fisher:

Don't ask me how long, it's been longtime.

Fintan Walton:

But long enough to build up an experience of the biotech industry and bit of a biotech sector, first of all just for the audience could you remind them little bit about the types of funds that you manage, and the types of investments you are making?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

David Fisher

Venture Partner

At the time of recording this PTV interview David Fisher serves as Venture Partner of Brandon Capital Partners. David is a Venture Partner with Brandon Capital Partners having helped found the business in 2007. David had previously established, Brandon Capital Management, the investment manager for three life sciences Pooled Development Funds in 1999. Before this, David was foundation CEO of Peptech Limited. During this period, Peptech Limited went from a start-up to having R&D operations in Australia, the UK, the US and manufacturing operations in Denmark. Prior to Peptech David spent ten years with Pharmacia AB (now part of Pfizer Inc), including five years at their head office in Sweden. David is a director of Signostics Ltd, Global Kinetics Corporation Pty Ltd, Nanosonics Ltd and Aeris Environmental Ltd. He is a past president of the Australian Biotechnology Association and past chairman of the CSIRO's Division of Animal Production Industry Advisory Committee. He has a first class Honours degree in Rural Science, a PhD in Chemical Engineering from the University of Sydney and a Masters degree in Applied Finance and Investments from the Financial Services Institute of Australasia (Finsia). David is a Fellow of Finsia and a member of AusBiotech.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Brandon Capital Partners

Brandon Capital Partners (BCP) makes seed and venture capital investments into emerging businesses in the high-growth life science industry. In addition to capital, the company enables entrepreneurs to access the resources needed to build successful businesses. We approach each investment as a collaborative alliance. Brandon Capital Partners is passionate about turning good science into improved medical outcomes for everyone. BCP's team has a record of accomplishment of successful life science investment as well as a history of working in research, operations and business development in the life sciences industry. Brandon Capital Partners was established in 2007, building on the success of its predecessor, Brandon Capital Management, established in 1999.